Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Opthea ( (AU:OPT) ) has issued an announcement.
Opthea Limited has announced the cessation of Susan Orr as a director, effective June 2, 2025. This update, provided under listing rule 3.19A.3, includes details of her interests in unquoted options to purchase shares, which may have implications for the company’s governance and strategic direction.
The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited is a company operating in the biotechnology industry, focusing on developing therapies for eye diseases. The company is primarily engaged in the research and development of treatments for conditions such as wet age-related macular degeneration and diabetic macular edema.
YTD Price Performance: -25.93%
Average Trading Volume: 6,651,653
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
Find detailed analytics on OPT stock on TipRanks’ Stock Analysis page.